
    
      Phase 3 non-treatment study in which Year 2 to Year 5 year follow-up of subjects who received
      AA4500 in the 9-month open-label studies (AUX-CC-854 and AUX-CC-856) or the 12-month
      double-blind with open-label extension studies (AUX-CC-857/AUX-CC-858 and AUX-CC-859). After
      completion of one of the above mentioned studies, subjects are enrolled and followed once a
      calendar year for 4 consecutive years with at least 6 months between consecutive visits.
    
  